Daily Respiratory Research Analysis
Analyzed 98 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies span clinical practice, pathogen biology, and vaccine policy. A double-blind RCT (MIST+) shows intranasal saline resolves pediatric sleep-disordered breathing symptoms as effectively as steroids. Mechanistic work reveals H5Ny influenza A viruses evolved binding to avian-type mucin O-glycans, increasing binding to human trachea. A PLoS Medicine benefit–risk model suggests maternal RSV vaccination from 27–36 gestational weeks favors benefits over potential preterm birth risks.
Research Themes
- Non-surgical management of pediatric obstructive sleep-disordered breathing
- Evolving receptor specificity of avian influenza and human spillover risk
- Gestational-age–targeted maternal RSV vaccination policy
Selected Articles
1. Intranasal Treatments for Children With Sleep-Disordered Breathing: The MIST+ Randomized Clinical Trial.
After a 6-week saline run-in, an additional 6 weeks of intranasal mometasone did not improve symptom resolution compared with continued saline in children with obstructive sleep-disordered breathing. Approximately half of participants had symptom resolution after 12 weeks total, supporting intranasal saline as an effective first-line strategy before polysomnography or surgery.
Impact: A well-designed RCT delivers a practice-changing negative result, indicating no added benefit of intranasal steroids over saline for short-term management of pediatric OSDB.
Clinical Implications: Recommend a 3-month course of once-daily intranasal saline as first-line management for pediatric OSDB before specialist referral, polysomnography, or adenotonsillectomy consideration.
Key Findings
- After saline run-in, symptom resolution with intranasal steroid vs saline was similar: 35.6% vs 36.4% (P=0.93).
- Nearly one-third (29.5%) had symptom resolution after the initial 6-week saline run-in.
- No differences in secondary outcomes (behavior, quality of life, parental perception of surgery need); no subgroup showed preferential response.
Methodological Strengths
- Double-blind, placebo-controlled RCT with standardized 6-week saline run-in.
- Adjusted analyses for site and baseline; pragmatic clinical endpoints relevant to decision-making.
Limitations
- Primary outcomes were symptom-based; limited objective polysomnography data.
- Modest randomized sample (n=93) and 12-week horizon may miss longer-term effects.
Future Directions: Evaluate longer-term outcomes, objective sleep metrics, and cost-effectiveness of a saline-first strategy; identify phenotypes predicting saline responsiveness.
IMPORTANCE: Symptoms of obstructive sleep apnea are common in childhood and associated with significant comorbidity. Surgical treatment with adenotonsillectomy is first-line treatment but medical treatments show potential to improve symptoms and reduce the need for surgery. OBJECTIVE: To determine the efficacy of 6 weeks of intranasal steroid (INS) compared with saline in children with obstructive sleep-disordered breathing (OSDB) with persistent symptoms after a 6-week intranasal saline run-in. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, randomized clinical trial involving specialist clinic waitlists at 2 sites in Australia. Included were children aged 3 to 12 years. Study data were analyzed from January to June 2025. INTERVENTIONS: All children received once-daily intranasal saline for 6 weeks (run-in). Those with persisting symptoms (SDB score ≥-1) were randomized to either once-daily intranasal mometasone furoate, 50 µg, (INS) or continued saline for a further 6 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was symptom resolution (SDB score <-1). Secondary outcomes included behavior, quality of life, and parental perception of need for surgery. Analyses were adjusted for site and baseline measures.
2. The receptor binding properties of H5Ny influenza A viruses have evolved to bind to avian-type mucin-like O-glycans.
Clade 2.3.4.4b H5Ny viruses evolved to bind avian-type mucin O-glycans (e.g., core 3 sialyl-Lewisx, Sia-Gal-β3GalNAc) not recognized by classical avian H5 strains. Crystallography delineated glycan-HA interactions, and tissue studies showed enhanced binding to human trachea despite lack of human-type receptor binding, implicating O-glycan recognition in continued spillover.
Impact: Reveals a novel receptor repertoire for emergent H5Ny clade with structural resolution, reframing host-range assessment beyond classical sialic acid linkages.
Clinical Implications: Enhances risk assessment for zoonotic spillover by prioritizing surveillance of O-glycan binding in H5Nx strains; informs glycan-array design and tissue tropism assays used in pandemic preparedness.
Key Findings
- H5Ny clade 2.3.4.4b viruses bind core 3 sialyl-Lewisx and Sia-Gal-β3GalNAc O-linked glycans not recognized by classical H5 or other avian viruses.
- Crystal structures resolved HA interactions with four O-glycans from a 2016 2.3.4.4b H5 HA, defining structural determinants of binding.
- Despite no binding to human-type receptors, broad receptor specificity increased binding to human tracheal tissues, suggesting a mechanism for spillover.
Methodological Strengths
- Custom synthesis of 25 distinct O-linked glycans with fucosylation/sulfation diversity.
- Integrative structural biology (X-ray crystallography) and ex vivo human tracheal tissue binding.
Limitations
- Binding data do not equate to transmissibility; no in vivo infection/transmission studies presented.
- Human-type receptor non-binding persists; public health relevance depends on additional adaptive steps.
Future Directions: Test in vivo infectivity/transmission in mammalian models, quantify O-glycan distribution across human airway niches, and incorporate O-glycans into standardized surveillance glycan panels.
Highly pathogenic H5Ny influenza A viruses are causing unprecedented, season-independent outbreaks across avian and mammalian species, including dairy cattle, a novel reservoir. The sialoside-binding properties of influenza A hemagglutinin (HA) are strongly related to its ability to infect and transmit between hosts. Mucin-like O-glycans, omnipresent in respiratory tracts, have been understudied as viral receptors due to their complexity. To address this, we synthesized 25 O-linked glycans with diverse sialosides, including modifications by fucosides and sulfates. Our findings reveal that H5Ny 2.3.4.4b viruses bind core 3 sialyl-Lewisx and Sia-Gal-β3GalNAc, O-linked glycans not recognized by classical H5 or other avian viruses. By determining crystal structures, we resolved the structural features of four glycans in an H5 hemagglutinin (HA) from a 2016 2.3.4.4b virus. While these viruses do not bind human-type receptors, their broad receptor specificity enhances binding to human tracheal tissues, suggesting that O-glycan recognition could contribute to the continues spillover of this clade.
3. The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.
Assuming a causal link between maternal RSVpreF and preterm birth, vaccination at 24–36 weeks’ gestation may not yield a favorable benefit–risk balance in South Africa, whereas vaccination at 27–36 weeks generally favors benefits. Results are highly sensitive to gestational age windows and limited to mortality outcomes.
Impact: Provides timely, context-specific benefit–risk estimates to guide maternal RSV vaccination policy where potential preterm birth signals exist.
Clinical Implications: Programs should preferentially schedule maternal RSVpreF administration at ≥27 weeks’ gestation and continue monitoring gestational age-specific outcomes; local burden and GA distribution critically shape benefit–risk.
Key Findings
- Estimated reduction of 31 (95% CrI: 27–35) RSV-associated infant deaths per 100,000 live births among vaccinated mothers.
- If preterm risk is causal at 24–36 weeks, model suggests 1.4 (95% CrI: −1.4 to 6.9) excess neonatal deaths per RSV death averted.
- At 27–36 weeks vaccination, 97% of simulations favored benefits over risks; results are sensitive to the gestational age window.
Methodological Strengths
- Combines South Africa-specific RSV burden and gestational age–specific neonatal mortality with credible intervals.
- Explores alternative gestational age windows and presents probabilistic outcomes.
Limitations
- Assumes causality for preterm birth risk; does not include morbidity outcomes beyond mortality.
- Small numbers of preterm births introduce wide uncertainty; generalizability may vary by setting.
Future Directions: Incorporate morbidity outcomes (e.g., ICU admissions), refine GA-specific risk estimates with post-licensure surveillance, and compare strategies alongside infant monoclonal antibodies.
BACKGROUND: Maternal respiratory syncytial virus (RSV) vaccine, RSV prefusion F protein vaccine (RSVpreF (Abrysvo)), was found to be safe and efficacious in the MATISSE trial. However, post-hoc stratified analyses identified an excess of preterm births in the intervention arm in two upper-middle-income countries, most prominently in South Africa. This study weighs the potential benefits and risks in mortality associated with maternal RSV vaccination in South Africa, assuming the increased risk of preterm births observed in the trial was caused by vaccination. METHODS AND FINDINGS: We compared the estimated RSV-associated infant deaths averted by vaccination (benefits) and neonatal mortality potentially associated with vaccine-associated risk in preterm birth (risks) in South Africa. The benefit model estimated the South African RSV disease burden in 2011-2016 and waning vaccine protection during infancy. The risk model estimated excess neonatal mortality using gestational age (GA)-specific mortality data from the Drakenstein Child Health Study and the GA-specific birth distribution in South Africa in the MATISSE trial, but did not incorporate the mortality risk found in the MATISSE vaccine trial in which no excess deaths occurred. The benefit model estimated that vaccination would reduce RSV-associated infant deaths by 31 (95% credible interval (Crl): 27, 35) per 100,000 live births born to vaccinated mothers in South Africa. Using the number of infants born to mothers vaccinated at 24-36 GA weeks in the MATISSE trial, if the association in South Africa between vaccination and preterm birth is actually causal, the risk model suggested that neonatal deaths would increase by 44 (95%CrI: -43, 210), totaling 1.4 (95%CrI: -1.4, 6.9) excess neonatal deaths for every infant RSV death prevented. When this was changed to the number of infants born to mothers vaccinated at 27-36 GA weeks in the MATISSE trial, the predicted risks dropped and in 97% of the simulations the benefits outweighed the risks. The outcome was sensitive to the GA window that we used to determine which infants to include in the analysis. The study was limited by only considering mortality associated with RSV disease and preterm birth.